---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029022"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:50:04.993906+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics appoints Dr. Jonathan Fox to board of directors

## Summary
- Dr. Jonathan Fox appointed as Class III director, term expiring at 2024 annual meeting.
- He is President and CMO of BridgeBio Pharma and former CMO of MyoKardia, inventor of Camzyos.
- Compensation includes $38k annual cash retainer, $4k for Nominating Committee, and stock option with ~$300k grant date fair value.
- Company plans to advance EDG-7500 towards Phase 1 trial in HCM in H2 2023.
- No arrangements or transactions requiring disclosure under Item 404(a).

## SEC filing metadata
- accession: 0001104659-23-029022
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/0001104659-23-029022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/tm238572d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029022
- JSON: https://secwatch.observer/filing/0001104659-23-029022.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029022.txt

## Key facts
- Executive change
  Dr. Jonathan Fox was appointed as Director at Edgewise Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 2, 2023, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Dr. Jonathan Fox to serve (i) as a Class III director, with a term expiring at the Company’s 2024 annual meeting of stockholders, and (ii) as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/0001104659-23-029022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.